TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05577169

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mind-body skills
Description: The purpose of mind-body medicine is to use conscious thoughts and actions to positively impact autonomic responses from the brain as well as coping mechanisms for life's stresses. Examples of mind-body skills include deep breathing exercises, meditation, drawing, guided imagery, journaling, affirmations, and biofeedback.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diabetes education
Description: When children and adolescents are diagnosed with diabetes, education is typically focused on the parents; as our older adolescents prepare to transition to adult care with full responsibility of their health, the goal of short education sessions is to review the basics of T1D along with addressing each individual's needs and questions as they make this transition.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diabetes education
Description: When children and adolescents are diagnosed with diabetes, education is typically focused on the parents; as our older adolescents prepare to transition to adult care with full responsibility of their health, the goal of short education sessions is to review the basics of T1D along with addressing each individual's needs and questions as they make this transition.
Study: NCT06130579

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IFN-Α
Description: Leukemia-associated immunophenotyping (LAIPs) was performed by flow cytometry at +1 month and +2 month after HSCT. If MRD was negative on two consecutive flow cytometry assays, interferon-α prophylaxis was initiated on day +75 after transplantation, and cyclosporine was tapered on day +100 after transplantation. The dose of interferon-α was 3 million units/time, subcutaneously injected twice a week. Cycles were given every 4 weeks until hematologic relapse or up to 6 cycles.
Study: NCT05303090

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: H101
Description: H101 intratumorally injection starts at day 0.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Tislelizumab plus lenvatinib will be initiated on day 1. Tislelizumab will be administered at 200 mg i.v. every 3 weeks orally daily every 3 weeks until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
Study: NCT01095900

Intervention type: PROCEDURE
Intervention: conservative lateral internal sphincterotomy

Intervention type: PROCEDURE
Intervention: Intra-sphincteric Botulinum-toxin injection
Study: NCT05437861

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Intervention
Description: A short conversation with the participant regarding their use of opioids will be conducted. During the conversation the participants potential drug dependency will be uncovered. Further the pros and cons of weaning of the medication will be explained and a new treatment plan will be proposed.
Study: NCT04774237

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BRIMOCHOL™
Description: A single drop in each eye at a visit.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BRIMOCHOL™ F
Description: A single drop in each eye at a visit.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carbachol
Description: A single drop in each eye at a visit.
Study: NCT05404256

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Radical gastrectomy +D2 lymphadenectomy+TissuePatchTM to seal pancreatic tissue surface
Description: Radical gastrectomy +D2 lymphadenectomy+TissuePatchTM to seal pancreatic tissue surface

Intervention type: OTHER
Group type: OTHER
Intervention: Radical gastrectomy +D2 lymphadenectomy
Description: Radical gastrectomy +D2 lymphadenectomy
Study: NCT05421702

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopic conventional colectomy
Description: Laparoscopic colectomy with only lymph node dissection up to level 2 lymph nodes D2.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopic complete mesocolic excision
Description: Laparoscopic colectomy with lymphovascular dissection from level 3 lymph nodes or more D3.
Study: NCT05315206

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Citicoline
Description: The patient will be given 10 ml of Citicoline oral solution (Neurotidine ®) once a day in the morning for 1 year. To patients will be given 4 bottles containing 500 ml of Citicoline and the relative instructions for administration. After 6 months, the patient will bring back the used bottles and will be given additional 4 bottles containing Citicoline (Neurotidine ®). Again at the end of this 6 month period the patient will bring back the used bottles.~Each bottle of Neurotidine will contain: water; fructose; Citicoline (500 mg per 10 ml); acidity regulators: sodium citrate, sodium hydroxide; preservative: potassium sorbate; dye: riboflavine.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The patient will be given 10 ml of an oral solution of Placebo. Each bottle of Placebo, the solution of which will be indistinguishable from the active product in terms of appearance and flavor, will contain: water; fructose; acidity regulators: sodium citrate, sodium hydroxide; preservative: potassium sorbate; dye: riboflavin
Study: NCT06327503

Intervention type: OTHER
Intervention: saliva samples collecting
Description: non-invasive collection of unstimulated whole saliva by spitting method into sterile plastic container

Intervention type: OTHER
Intervention: saliva samples collecting
Description: non-invasive collection of unstimulated whole saliva by spitting method into sterile plastic container
Study: NCT06277869

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thermal Jacket
Description: In the intervention group, the enrolled preterm or low birthweight eligible neonates gets the intervention Thermal Jacket as well as Kangaroo Mother Care.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Kangaroo Mother Care
Description: Skin-to-Skin care, provided by primary caregiver.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Kangaroo Mother Care
Description: Skin-to-Skin care, provided by primary caregiver.
Study: NCT05482373

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oleuropein from olive tree
Description: The capsules intake will last for a total of 4 months.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The capsules intake will last for a total of 4 months.
Study: NCT05097092

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Orthopedic immobilization
Description: Orthopedic immobilization will be performed with a sling and swathe.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Orthopedic immobilization
Description: Orthopedic immobilization will be performed with a sling and swathe.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Unilateral resistance training
Description: Unilateral resistance training will be performed by the dominant arm of the immobilization + unilateral resistance training group during Phase 1.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bilateral resistance training
Description: Bilateral resistance training will be performed by both arms in both groups during Phase 2.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bilateral resistance training
Description: Bilateral resistance training will be performed by both arms in both groups during Phase 2.
Study: NCT06337916

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cervical Stabilization Exercise
Description: The cervical stabilization exercise group will receive cervical stabilization exercises 1 session a day, 3 days a week for 6 weeks. Patients will do their exercises in the first 3 weeks accompanied by a physiotherapist, and in the last 3 weeks as a home exercise program.Before the start of the treatment, at the end of the 3rd week and at the end of the 6th week; pain intensity, level of neck disability, quality of life, cervical range of motion and cervical joint position sense will be evaluated and both groups will be compared in these parameters.Demographic information of the patients to be included in the study will be recorded . The patients will be compared to evaluate for Visual Analogue Scale (VAS), Neck Disability Index (NDI) and Short Form (SF-36), cervical range of motion and cervical joint position sense after intervention. Cervical range of motion and cervical joint position sense will be evaluated with the Cervical Range of Motion Deluxe Device (CROM).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cervical Standard Exercise Group
Description: The patients in cervical standard exercise group will receive conventional cervical exercise for 6 weeks, 3 days a week, 1 session a day. Patients will do their exercises in the first 3 weeks accompanied by a physiotherapist, and in the last 3 weeks as a home exercise program.Before the start of the treatment, at the end of the 3rd week and at the end of the 6th week; pain intensity, level of neck disability, quality of life, cervical range of motion and cervical joint position sense will be evaluated and both groups will be compared in these parameters.Demographic information of the patients to be included in the study will be recorded . The patients will be compared to evaluate for Visual Analogue Scale (VAS), Neck Disability Index (NDI) and Short Form (SF-36), cervical range of motion and cervical joint position sense after intervention. Cervical range of motion and cervical joint position sense will be evaluated with the Cervical Range of Motion Deluxe Device (CROM).
Study: NCT04786223

Intervention type: DRUG
Group type: OTHER
Intervention: C-11 ER-176
Description: Participants will receive a one-time administration of C-11 ER176 and undergo a PET/CT imaging study. Blood samples for plasma biomarker testing will be obtained as part of the study.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Blood Test
Description: Participants will undergo a one time venipuncture blood collection to evaluate the presence of inflammatory and genetic markers.
Study: NCT04949750

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Paper - based cognitive training
Description: Cognitive training
Study: NCT06124755

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Viabahn endoprosthesis group
Description: Patients underwent endovascular treatment for femoropopliteal lesions. The lesion will be treated by Viabahn endoprosthesis.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Drug-coated balloon group
Description: Patients underwent endovascular treatment for femoropopliteal lesions. The lesion will be treated by drug-coated balloon.
Study: NCT05118230

Intervention type: OTHER
Intervention: Inclisiran
Description: Prospective observational study. There is no treatment allocation. Chinese Patients who receive inclisiran in authorized health institutions are eligible to enroll into this study.
Study: NCT05303090

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenvatinib
Description: lenvatinib (bodyweight ≥ 60 kg, 12 mg; \< 60 kg, 8 mg) orally daily every 3 weeks until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
Study: NCT05923229

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Walking Therapy (MBWT)
Description: MBWT is a modified version of the Mindfulness Based Stress Reduction (MBSR) program that incorporates more walking mediations and is acceptable for people with Parkinson disease and freezing of gait.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Freezing of Gait (FOG) Education
Description: Participants will receive materials to read weekly about FOG and track their usual care regimens.
Study: NCT06371430

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dental Implant insertion and tooth extraction
Description: The osteotomies were carried out at a speed of 800 rpm, using sequential burs of similar diameter for both the maxilar and the mandibular side. The drilling protocols followed the recommendations provided by the manufacturer, the Galaxy-Ziacom implant system, for standard drilling.~The insertion of the implants was initiated using a motor handpiece at a speed of 20-50 rpm, without irrigation. The installation process was completed using a manual surgical torque wrench indicator. The maximum torque value (Ncm) reached at the end of implant insertion was recorded as the insertion torque (IT). A total of 264 implants were inserted in 33 patients, 160 implants were post-extraction and 104 implants were inserted after at least one-month post-extraction. The sutures were typically removed 1 week after the surgery, during the postoperative follow-up appointment.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Dental Implant insertion and tooth extraction
Description: The osteotomies were carried out at a speed of 800 rpm, using sequential burs of similar diameter for both the maxilar and the mandibular side. The drilling protocols followed the recommendations provided by the manufacturer, the Galaxy-Ziacom implant system, for standard drilling.~The insertion of the implants was initiated using a motor handpiece at a speed of 20-50 rpm, without irrigation. The installation process was completed using a manual surgical torque wrench indicator. The maximum torque value (Ncm) reached at the end of implant insertion was recorded as the insertion torque (IT). A total of 264 implants were inserted in 33 patients, 160 implants were post-extraction and 104 implants were inserted after at least one-month post-extraction. The sutures were typically removed 1 week after the surgery, during the postoperative follow-up appointment.
Study: NCT05649345

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TR64
Description: TR64 tablets will be given daily for 28 days in 28-day cycles until there appears evidence of progressive disease, intolerable toxicity, or the subject discontinues from the study treatment for other reasons.
Study: NCT04707196

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nonsteroidal Aromatase Inhibitor (NSAI)
Description: Letrozole or anastrozole administered orally (physician choice)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Administered intramuscularly
Study: NCT06371430

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Dental Implant insertion and tooth extraction
Description: The osteotomies were carried out at a speed of 800 rpm, using sequential burs of similar diameter for both the maxilar and the mandibular side. The drilling protocols followed the recommendations provided by the manufacturer, the Galaxy-Ziacom implant system, for standard drilling.~The insertion of the implants was initiated using a motor handpiece at a speed of 20-50 rpm, without irrigation. The installation process was completed using a manual surgical torque wrench indicator. The maximum torque value (Ncm) reached at the end of implant insertion was recorded as the insertion torque (IT). A total of 264 implants were inserted in 33 patients, 160 implants were post-extraction and 104 implants were inserted after at least one-month post-extraction. The sutures were typically removed 1 week after the surgery, during the postoperative follow-up appointment.
Study: NCT04915157

Intervention type: DEVICE
Group type: OTHER
Intervention: Spinal Cord Stimulator
Description: All patients will receive an implanted spinal cord stimulator.

Intervention type: DEVICE
Group type: OTHER
Intervention: Spinal Cord Stimulator
Description: All patients will receive an implanted spinal cord stimulator.
Study: NCT04993508

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PSA test
Description: testing for blood levels of PSA

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: PSA test
Description: testing for blood levels of PSA

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: PSA test
Description: testing for blood levels of PSA

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: PSA test
Description: testing for blood levels of PSA

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: multiparametric prostate Magnetic Resonance Imaging (mpMRI)
Description: mpMRI acquisition and reporting will be performed according to the current version of the Prostate Imaging-Reporting and Data System (PI-RADS). MpMRI will be performed at the different study centers on a 3 Tesla MR scanner using multi-phased array surface coil. MpMRI includes T1-weighted and T2-weighted imaging (T1WI, T2WI), diffusion-weighted imaging (DWI), and dynamic contrast-enhanced imaging (DCE-MRI). Hyoscine butyl bromide will be administered to optimize image quality. Prostate imaging quality will be assessed by the prostate imaging quality score (PI-QUAL). In case of contraindications to MRI contrast agents, DCE will be omitted. In case of contraindications to hyoscine butyl bromide, it will be omitted. Lesions with a PI-RADS score of ≥ 4 and 3 with PSAD \> 0.15 will considered suspicious for csPCa.
Study: NCT05005338

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB122 (DNL151)
Description: Oral doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C] BIIB122 ([14C] DNL151)
Description: Intravenous doses
Study: NCT05758922

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZ-3102 (Dose 1)
Description: Pharmaceutical form: capsule~Route of administration: oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical form: capsule~Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZ-3102 (Dose 2)
Description: Pharmaceutical form: capsule~Route of administration: oral
Study: NCT05016544

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: inetetamab
Description: All dose levels will receive 8 mg/kg loading dose for cycle 1, followed by 6 mg/kg in subsequent cycles, every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pytotinib
Description: Starting pytotinib Dose of 240mg:~Cohort 1: pyrotinib 240mg p.o. d1 to d21, q3w; Cohort 2: pyrotinib 320mg p.o. d1 to d21, q3w; Cohort 3: pyrotinib 400mg p.o. d1 to d21, q3w.
Study: NCT06264544

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: zinc, selenium, and L-tyrosine in SEPP1
Description: zinc, selenium, and L-tyrosine in SEPP1 polymorphism

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo comparator in SEPP1 polymorphism group
Study: NCT04404478

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: B-SWELL: Midlife Black Women's Stress Reduction Wellness Program
Description: Stress reduction and culturally tailored information on healthy lifestyle behaviors will be used to increase healthy lifestyle behaviors according to the AHA's Life's Simple 7. Focus of intervention on per support, goal setting, stress reduction, and culturally relevant information.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: WE: Wellness program for Midlife Black Women
Description: Culturally tailored information will be provided about healthy lifestyle behaviors will be used to increase healthy lifestyle behaviors according to the AHA's Life's Simple 7. Focus of intervention on peer support and culturally relevant content.
Study: NCT05606263

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caldonirimab and Nimotuzumab
Description: Subjects will receive caldonirimab (6mg/Kg, q2w) until disease progression or for a maximum of 12 months, and Nimotuzumab (400mg/time, q2w) for a total of 8 cycles
Study: NCT04479722

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Left atrial appendage closure procedure
Description: Implant LAAC system in LAA through percutaneous intervention

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Left atrial appendage closure procedure
Description: Implant LAAC system in LAA through percutaneous intervention
Study: NCT04860414

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: Fasting blood glucose, dosage of acylated and non-acylated ghrelin, leptin, insulin and serotonin.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: Fasting blood glucose, dosage of acylated and non-acylated ghrelin, leptin, insulin and serotonin.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Blood sampling
Description: Fasting blood glucose, dosage of acylated and non-acylated ghrelin, leptin, insulin and serotonin.
Study: NCT04867707

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanamivir
Description: 5 days of treatment with 10mg zanamivir inhaler BID
Study: NCT06461078

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Radotinib HCl
Description: 1. Brand name/manufacturer: Supect Cap./IL-YANG PHARM. Co., Ltd.~2. Active ingredient: radotinib HCl 106.8mg (100mg as radotinib) or HCl 213.6mg (200mg as radotinib)~3. Appearance and formulation: hard capsule with a light blue cap and a body containing pale yellow powder~4. Storage conditions: Store in an airtight light proof container at room temperature.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Radotinib HCl
Description: 1. Brand name/manufacturer: Supect Cap./IL-YANG PHARM. Co., Ltd.~2. Active ingredient: radotinib HCl 106.8mg (100mg as radotinib) or HCl 213.6mg (200mg as radotinib)~3. Appearance and formulation: hard capsule with a light blue cap and a body containing pale yellow powder~4. Storage conditions: Store in an airtight light proof container at room temperature.
Study: NCT06487221

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avutometinib
Description: 3.2mg orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Defactinib
Description: 200 mg orally